Aarvik Therapeutics, an innovative, ADC-focused biotechnology company dedicated to engineering precision medicines for cancer therapy, is pleased to announce an investment by Laurus Labs, India in Aarvik’s recently-concluded Series Seed 2 financing round.
Since launching in 2021, Aarvik has developed its proprietary MUTTA™ (MUlti-epitope Targeting Tetravalent Antibody) plaform with a focus on developing next generation antibody drug conjugates (ADCs) that can expand the success of ADCs beyond a limited number of targets. Aarvik’s comprehensive approach facilitiates the lowering of the minimum effective dose (MED) while maintaining or improving the maximum tolerated dose (MTD) thereby significantly improving the therapeutic window. The Series Seed 2 round, which had investments from multiple investors including Laurus, is an acknowledgement of the substantial progress made by Aarvik on the MUTTA™ platform and will allow Aarvik to further advance its exciting pipeline of ADC assets.
“As part of our global support of innovation and progress in healthcare, we are delighted to invest in Aarvik’s efforts to pursue breakthroughs in oncology therapies,” said Dr. Satyanarayana Chava, Founder & CEO of Laurus Labs. “We look forward to a highly productive collaboration that results in tangible benefits for patients across the globe.”
“Aarvik is delighted to welcome Laurus Labs as an investor and a partner in our efforts to pursue improved therapies for hard-to-treat indications in cancer,” said Jagath Reddy Junutula, PhD, Co-founder, President and CEO of Aarvik Therapeutics. “Our mission to provide transformational benefits for cancer patients is greatly strengthened by our ability to work with outstanding companies like Laurus Labs.”
